RhumbLine Advisers’s TriSalus Life Sciences TLSI Stock Holding History

RhumbLine Advisers’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Buy	30,121 +15,079	+100%	+$59.9K	﹤0.01%	3421
2026 Q1	$60.2K	Sell	15,042 -386	-3%	-$1.89K	﹤0.01%	3560
2025 Q4	$108K	Buy	15,428 +403	+3%	+$2.26K	﹤0.01%	3439
2025 Q3	$69.9K	Sell	15,025 -1,438	-9%	-$6.73K	﹤0.01%	3600
2025 Q2	$89.7K	Buy	+16,463	New	+$88.3K	﹤0.01%	3563

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

RhumbLine Advisers's TLSI Position: Q2 2026 in Review

RhumbLine Advisers increased its TriSalus Life Sciences (TLSI) stake by 100% in Q2 2026, buying an estimated $59.9K and bringing the position to 30,121 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3421.

RhumbLine Advisers first reported a position in TLSI in Q2 2025 and has held it in 5 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

RhumbLine Advisers held 30,121 shares of TriSalus Life Sciences worth $137K as of Q2 2026.
RhumbLine Advisers bought 15,079 TriSalus Life Sciences shares in Q2 2026, an estimated $59.9K.
TriSalus Life Sciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3421 holding.
RhumbLine Advisers first reported a position in TriSalus Life Sciences in Q2 2025 and has held it in 5 quarters since.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.